It has been postulated that delivery of VEGF-C and VEGF-D may be able to promote regeneration of LEC via activation of the VEGFR-2 and/or VEGFR-3 RTKs, and thus may be a useful approach by which to treat lymphoedema (Szuba et al., 2002; Cheung et al., 2006; Ji, 2007). The gene discussed is FLT4; the disease is lymphedema.